Phase I and II studies have shown that despite sustained anti-tumor activity, the objective response rate to KRAS G12C inhibition oscillates widely according to the primary tumor site, ranging from 30% in bronchial cancers to 7% in colorectal cancers [21,43,44]. Here, KRAS is linked to neoplasm.